You are here
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler, Pineda, Horiuchi, Singh, Mahgoub, Coindreau, JacobsRheumatology International May 2016, Volume 36, Issue 5, pp 613–625
Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies.
Castañeda-Hernández, Szekanecz, Mysler, Azevedo, Guzman, Gutierrez, Rodríguez, KarateevJoint Bone Spine Volume 81, Issue 6, December 2014, Pages 471–477
Dörner, Strand, Cornes, Gonçalves, Gulácsi , Kay, Kvien, Smolen , Tanaka, Burmester.Annals of the Rheumatic Diseases, 75(6):annrheumdis-2016-209166 · March 2016
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trialThe Lancet, Volume 388, No. 10042, p343–355, 23 July 2016
Dual Cytokine Inhibition with ABT-122, a Tnf- and IL-17-Targeted Dual Variable Domain Immunoglobulin (DVD-Ig(tm)): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis [abstract]
Mark C. Genovese1, Michael Weinblatt2, Heikki T. Mansikka3, Paul M. Peloso3, Kun Chen3, Yihan Li3, John Liu3 and Robert J. Padley3Arthritis Rheumatol. 2016; 68 (suppl 10).
Interview with Prof. Iain McInnes at APLAR 2016, ShanghaiSummary With new medicines – and better ways of using them – the last decade has seen a remarkable change...